Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-25
2008-11-18
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S262000, C544S118000, C544S350000, C544S236000, C514S262100, C514S252160, C514S248000, C514S300000, C546S119000
Reexamination Certificate
active
07452880
ABSTRACT:
Compounds of the formula I:where A, B, X, Y, Z, k, R1, R2and R3are those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a patient.
REFERENCES:
patent: 3821382 (1974-06-01), Hoyle et al.
patent: 3948913 (1976-04-01), Howarth et al.
patent: 4020072 (1977-04-01), Hoehn
patent: 4044130 (1977-08-01), Howarth et al.
patent: 7217710 (2007-05-01), Adams et al.
patent: 2002/0193610 (2002-12-01), Woltering et al.
patent: 2003/0207900 (2003-11-01), Chen et al.
patent: 2004/0176325 (2004-09-01), Munson et al.
patent: 2004/0180896 (2004-09-01), Munson et al.
patent: 2005/0197340 (2005-09-01), Arora et al.
patent: 2005/0203091 (2005-09-01), Arora et al.
patent: 2005/0277655 (2005-12-01), Ding et al.
patent: 2052719 (1971-09-01), None
patent: 0 104 522 (1991-05-01), None
patent: 1 148 054 (2001-10-01), None
patent: 937.725 (1963-09-01), None
patent: WO 98/09961 (1998-03-01), None
patent: WO 98/40384 (1998-09-01), None
patent: WO 99/23077 (1999-05-01), None
patent: WO 00/27627 (2000-05-01), None
patent: WO 01/98301 (2001-12-01), None
patent: WO 02/22586 (2002-03-01), None
patent: WO 02/051837 (2002-07-01), None
patent: WO 02/059088 (2002-08-01), None
patent: WO 03/000187 (2003-01-01), None
patent: WO 03/009852 (2003-02-01), None
patent: WO 03/029209 (2003-04-01), None
patent: WO 03/062392 (2003-07-01), None
patent: WO 03/068754 (2003-08-01), None
patent: WO 03/099820 (2003-12-01), None
patent: WO 2004/078116 (2004-09-01), None
patent: WO 2005/085248 (2005-09-01), None
patent: WO 2005085248 (2005-09-01), None
Fijen (Clinical & Experimental Immunology, 2001, 124, 2-20).
Gong et. al. (Chinese Chemical Letters, 2002, 13(7), 613-616).
Hashimoto (J Pharmacol Exp Ther., 2000, 293(2), 370-375).
Esper et. al. (Expert. Opin. Investig. Drugs, 2005, 14(5), 633-645).
Jones et al; “British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.” Gut 2000, (Suppl II)47:ii1-ii19.
Badger, A. M., et al. “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin shock and Immune Function,”J. Pharm. Exp. Therap. (1996) vol. 279 (1) pp. 1453-1461.
Badger, A. M., et al, “SB 203580 Inhibitors p38 Mitogen-Activated Protein Kinase, Nitric Oxide Production, and Inducible Nitric Oxide Synthase in Bovine Cartilage-Derived Chondrocytes,”J. Immunol. (1998) vol. 161, pp. 467-473.
Badger, A. M., et al. “Disease-Modifying Activity of SB242235, A Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, in Rat Adjuvant-induced Arthritis,”Arthritis&Rheumatism(2000) vol. 43 (1) pp. 175-183.
Jackson, J.R., et. al., “Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models,”J. Pharma. Exp. Therap. (1998) vol. 284 (2) pp. 687-692.
Parasrampuria, D. A., et al., “Single-Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen-Activated Protein Kinase Inhibitors: A First-in-Human Study,”J. Clin. Pharmacol. (2005) vol. 43, pp. 406-413.
Pargellis, C. et. al., “Inhibitors of p38 Mitogen-Activated Protein Kinase for the Treatment of Rheumatoid Arthritis,”Current Opin. Investigational Drugs(2003) vol. 4 (5) pp. 566-571.
Studer, R. K., et al., “Chrondrocyte Response to Growth Factors is Modulated by p38 Mitogen-Activated protein Kinase Inhibitors,”Arthritis Research Ther. (2004) vol. 6, R56-64.
Wada, Y., et. al., “R-130823, a Novel Inhibitor of p38 MAPK, Ameliorates Hyperalgesia and Swelling in Arthritis Models,”Europ, J. Pharmacol. (2005) vol. 506, pp. 285-295.
Wadsworth, S. A., et. al., “RWJ 67657, a Potent, Orally Active Inhibitor of p38 Mitogen-Activated Protein Kinase,”J. Pharm. Exp. Therapeutics(1999) vol. 291 (2) pp. 680-687.
Arora Nidhi
Billedeau Roland Joseph
Dewdney Nolan James
Gabriel Tobias
Goldstein David Michael
Coleman Brenda
Hall Robert C.
Moore Susanna
LandOfFree
Substituted pyrazolo [3,4-d] pyrimidines and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazolo [3,4-d] pyrimidines and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazolo [3,4-d] pyrimidines and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4047525